The University of Chicago Header Logo


Mark J. Ratain to Drug Industry

This is a "connection" page, showing publications Mark J. Ratain has written about Drug Industry.
Connection Strength

  1. Combination therapy patents: a new front in evergreening. Nat Biotechnol. 2021 12; 39(12):1504-1510.
    View in: PubMed
    Score: 0.789
  2. Oncology micro-cap stocks: caveat emptor! J Natl Cancer Inst. 2011 Oct 19; 103(20):1488-9.
    View in: PubMed
    Score: 0.390
  3. Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy. J Clin Oncol. 2014 Aug 01; 32(22):2293-5.
    View in: PubMed
    Score: 0.118
  4. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15; 22(22):4442-5.
    View in: PubMed
    Score: 0.060
  5. Inside information: Financial conflicts of interest for research subjects in early phase clinical trials. J Natl Cancer Inst. 2004 May 05; 96(9):656-61.
    View in: PubMed
    Score: 0.058
  6. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.